A small number of confirmed cases of a rare and serious form of blood clot have caused federal health officials to request that the Johnson & Johnson Covid-19 vaccine be halted while they investigate. The Johnson and Johnson vaccine being put on hold could have an effect on vaccination efforts in senior living populations.
Johnson and Johnson Covid-19 vaccine side effects, according to the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are looking into six confirmed cases of cerebral venous sinus thrombosis in Johnson and Johnson Covid-19 vaccine recipients in the United States. Symptoms appeared six to thirteen days after vaccination in all six cases, which occurred in women aged 18 to 48. A small number of confirmed cases of a rare and serious form of blood clot have caused federal health officials to request that the Johnson & Johnson Covid-19 vaccine be halted while they investigate.
The decision was confirmed jointly by the two federal agencies on Tuesday, with the warning that the adverse consequences under consideration tended to be exceedingly rare. The agencies issued a joint statement saying, “Covid-19 vaccine protection is a top priority for the federal government, and we take all reports of health issues following Covid-19 vaccination very seriously.”
States and cities around the country rushed to halt their own vaccination programs during the evaluation period in response to the announcement. The delay, according to the White House, “would have no substantial effect on our vaccination schedule.” According to White House Covid-19 Response Coordinator Jeff Zients, the Johnson & Johnson vaccine accounts for less than 5% of all reported shots in guns in the United States.
On February 27, the Johnson & Johnson vaccine was officially approved for use on an emergency basis, just as the federal nursing home and assisted living vaccination program’s three-clinic plan was coming to an end at facilities around the country.
Outside of that initiative, CVS/Omnicare and Walgreens have halted use of Johnson & Johnson’s Covid-19 vaccine, citing federal health agencies’ recommendations, and are waiting for the CDC and FDA to take further action. Brookdale Senior Living (NYSE: BKD), the nation’s largest senior living provider, collaborated with Omnicare and did not use the Johnson & Johnson vaccine used during Pharmacy Relationship with Long-Term Care Program vaccination clinics, which concluded this week.
A company representative told Senior Housing News that a prolonged delay might affect the supply of potential vaccinations, such as those made possible by a collaboration with a local pharmacy, but that it was still too early to say if there would be any consequences.
Dr. Sandra Petersen, who is an advisor to Pegasus Senior Living’s health and wellness team and is heading the Covid-19 response, does not believe the delay would have a significant effect on senior living vaccination efforts. According to Phil Fogg, Jr., CEO of Milwaukie, Oregon-based Marquis Companies and its in-house long-term care pharmacy, Consonus Pharmacy, the results of the vaccine pause differ by situation.
Consonus is one of the seven long-term care pharmacy providers accredited by the CDC and the state to be a vaccine distributor in phase one of the Pharmacy Partnership for Long-Term Care Program, which includes Pfizer and Moderna vaccines.